{"id":1629,"date":"2025-05-27T13:10:57","date_gmt":"2025-05-27T11:10:57","guid":{"rendered":"https:\/\/imunologija.si\/?p=1629"},"modified":"2025-05-27T13:43:27","modified_gmt":"2025-05-27T11:43:27","slug":"obsevanje-dela-tumorja","status":"publish","type":"post","link":"https:\/\/imunologija.si\/en\/obsevanje-dela-tumorja\/","title":{"rendered":"Partial tumor irradiation to improve the efficacy of radiotherapy"},"content":{"rendered":"

Radiotherapy is a cancer treatment that uses irradiation to damage tumor cells and induce their death. As cancer cells die and release their antigens, the irradiation also acts like an anti-tumor vaccine, since immune cells within and around the tumor recognize these antigens and initiate anti-tumor responses. This makes the combination of radiotherapy and immunotherapy with immune checkpoint inhibitors (ICIs) particularly interesting and potentially effective. ICIs enhance the immune system\u2019s anti-tumor activity, enabling the body to destroy the cancer itself. However, in addition to damaging cancer cells, irradiation also harms immune cells within the tumor, which reduces the therapeutic effect. Therefore, a novel approach called partial irradiation (pIR) is being investigated, in which only part of the tumor is irradiated. This aims to stimulate the immune system without destroying all the immune cells.<\/p>\n\n\n\n

In a recent study by Pi\u0161ljar et al., the team investigated whether pIR combined with ICI immunotherapy could increase treatment efficacy. They compared pIR with full tumor irradiation (IR) in immune-cold mouse models of oral squamous cell carcinoma, a cancer typically treated with radiotherapy. Eighteen immune cell subpopulations in tumors were thoroughly evaluated before and after therapy using flow cytometry.<\/p>\n\n\n\n

Key findings of the study:<\/strong><\/p>\n\n\n\n